目的 探討應(yīng)用大株紅景天注射液聯(lián)合尼可地爾治療冠心病的臨床效果。方法 選取2016年6月-2018年1月深圳市龍華區(qū)人民醫(yī)院收治的冠心病患者126例，隨機(jī)分成對(duì)照組（63例）與治療組（63例）。對(duì)照組口服尼可地爾片，5 mg/次，3次/d。治療組在對(duì)照組基礎(chǔ)上靜脈滴注大株紅景天注射液，10 mL加入5%葡萄糖液250 mL，1次/d。兩組均連續(xù)治療14 d。觀察兩組患者心絞痛癥狀和心電圖療效，同時(shí)比較治療前后兩組患者E峰與A峰的速度比值（E/A）、左室射血分?jǐn)?shù)（LVEF）、血漿黏度（PV）、紅細(xì)胞比容（Hct）、乳酸脫氫酶（LDH）、肌酸激酶同工酶（CK-MB）、血清載脂蛋白（Apo）B/ApoA1比值、同型半胱氨酸（Hcy）、超敏C反應(yīng)蛋白（hs-CRP）、脂聯(lián)素（APN）、白細(xì)胞介素（IL）-35和頸動(dòng)脈超聲參數(shù)變化。結(jié)果 治療后，對(duì)照組心絞痛癥狀和心電圖總有效率分別為81.0%和76.2%，均分別顯著低于治療組的93.7%和90.5%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組E/A、LVEF值均顯著增加（P<0.05），PV、HCT值和血清LDH、CK-MB濃度均顯著降低（P<0.05），且治療后治療組這些指標(biāo)明顯優(yōu)于對(duì)照組（P<0.05）。治療后，兩組頸總動(dòng)脈IMT和內(nèi)徑值均顯著縮?。?i>P<0.05），且治療組IMT和內(nèi)徑值明顯小于對(duì)照組（P<0.05）。治療后，兩組血清ApoB/ApoA1比值和Hcy、hs-CRP濃度均顯著降低（P<0.05），APN、IL-35含量顯著上升（P<0.05），且治療后治療組上述指標(biāo)明顯優(yōu)于對(duì)照組（P<0.05）。結(jié)論 應(yīng)用大株紅景天注射液聯(lián)合尼可地爾治療冠心病可明顯改善心電圖和心功能，調(diào)節(jié)血液流變學(xué)狀態(tài)，延緩病情進(jìn)展，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Sofren Injection combined with nicorandil in treatment of coronary disease. Methods Patients (126 cases) with coronary disease in Longhua District People's Hospital from June 2016 to January 2018 were randomly divided into control (63 cases) and treatment (63 cases) groups. Patients in the control group were po administered with Nicorandil Tablets, 5 mg/time, three times daily. Patients in the treatment group were iv administered with Sofren Injection on the basis of the control group, 10 mL added into 5% glucose solution 250 mL, once daily. Patients in two groups were treated for 14 d. After treatment, the angina curative effect and the ECG efficacy was evaluated, and the changes of E/A, LVEF, PV, Hct, LDH, CK-MB, ApoB/ApoA1, Hcy, hs-CRP, APN, IL-35, and the carotid ultrasound parameters in two groups before and after treatment were compared. Results After treatment, the angina curative effect in the control group was 81%, and the ECG efficacy was 76.2%, which were significantly lower than 93.7% and 90.5% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the E/A and LVEF levels in two groups were significantly increased (P<0.05), but PV, HCT, LDH and CK-MB levels were significantly decreased (P<0.05), and these indicators in the treatment group after treatment were significantly better than those in the control group (P<0.05). After treatment, the IMT and internal diameter of common carotid artery in two groups were significantly reduced (P<0.05), and the IMT and internal diameter in the treatment group after treatment were significantly smaller than those in the control group (P<0.05). After treatment, the ApoB/ApoA1, Hcy and hs-CRP levels in two groups were significantly decreased (P<0.05), but APN and IL-35 levels were significantly increased (P<0.05), and these indicators in the treatment group after treatment were significantly better than those in the control group (P<0.05). Conclusion Sofren Injection combined with nicorandil in treatment of coronary disease can obviously improve the electrocardiogram and heart function, regulate the blood rheology and delay disease progress, which has a certain clinical application value.